Comparing two antibiotic combos for infection and kidney safety
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial compares two common antibiotic combinations to see which one is less likely to cause kidney injury in hospitalized patients. You may be eligible if you need treatment with vancomycin plus either piperacillin-tazobactam or cefepime.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed or suspected infection needing antibiotics.
- Your doctor agrees both antibiotic combinations are acceptable for you.
- You are expected to need at least 48 hours of antibiotics.
- You have not had dialysis or end-stage kidney disease.
- You do not have acute kidney injury at the start.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether melatonin can help protect the kidneys in people who are starting or continuing vancomycin, an antibiotic that can sometimes affect kidney function. If you qualify, you would take melatonin as an added prevention step while you’re on vancomycin.
This study watches how safely two common antibiotics (vancomycin and a combination called piperacillin/tazobactam) work together in hospitalized patients with serious infections. Researchers want to make sure the combination doesn't harm kidney function.
This trial tests a different way of giving vancomycin to children with sepsis to reduce the risk of kidney injury. It compares standard dosing to an approach that adjusts dose based on how the kidneys are working.
This trial studies how common antibiotics move through the body when someone is on kidney replacement therapy (dialysis), including when dialysis starts during treatment. The results may help doctors choose the right antibiotic dose and timing for better infection treatment.
This study compares two strong antibiotics—ceftazidime-avibactam and a high dose of meropenem given over a longer infusion—in patients with advanced liver disease who develop a hospital-acquired infection. The goal is to see which works better and is safer.
This study looks at how well a continuous kidney replacement therapy removes a common antibiotic combination (piperacillin and tazobactam) from the blood in intensive care patients. It may help doctors better dose the antibiotic for patients on this type of dialysis.
Hear when a new Acute Kidney Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.